Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Haferlach

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Leukemia|October 12, 2013
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patientsS Jeromin, S Weissmann, C Haferlach, et al.
Leukemia|February 6, 2009
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic featuresT Haferlach, A Kohlmann, H-U Klein, et al.
Leukemia|August 12, 2014
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroupsM-T Krauth, T Alpermann, U Bacher, et al.
Leukemia|September 24, 2013
The role of different genetic subtypes of CEBPA mutated AMLA Fasan, C Haferlach, T Alpermann, et al.
Leukemia|June 20, 2017
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasmsJ Rinke, J P Müller, M F Blaess, et al.
Leukemia|November 26, 2011
Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann, T Alpermann, V Grossmann, et al.
Blood Cancer Journal|January 14, 2014
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemiaS Weber, T Alpermann, F Dicker, et al.
Leukemia|September 13, 2014
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL statusM Schmidt, J Rinke, V Schäfer, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Leukemia|January 31, 2019
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasmsK A Rack, E van den Berg, C Haferlach, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Leukemia|October 12, 2013
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patientsS Jeromin, S Weissmann, C Haferlach, et al.
Leukemia|February 6, 2009
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic featuresT Haferlach, A Kohlmann, H-U Klein, et al.
Leukemia|August 12, 2014
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroupsM-T Krauth, T Alpermann, U Bacher, et al.
Leukemia|September 24, 2013
The role of different genetic subtypes of CEBPA mutated AMLA Fasan, C Haferlach, T Alpermann, et al.
Leukemia|June 20, 2017
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasmsJ Rinke, J P Müller, M F Blaess, et al.
Leukemia|November 26, 2011
Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann, T Alpermann, V Grossmann, et al.
Blood Cancer Journal|January 14, 2014
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemiaS Weber, T Alpermann, F Dicker, et al.
Leukemia|September 13, 2014
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL statusM Schmidt, J Rinke, V Schäfer, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Leukemia|January 31, 2019
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasmsK A Rack, E van den Berg, C Haferlach, et al.
Pageof 5